%201.svg)
Envisia Therapeutics, Inc.
Company Summary
Envisia Therapeutics, formed by Liquidia Technologies, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma.
Transaction Overview
- Envisia Therapeutics announced the completion of a $25 million in Series A financing
Significance of the Transaction
With ENV515, Envisia brings a potentially revolutionary approach to advancing glaucoma pharmacotherapy In addition to ENV515, Envisia is using its proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology platform to create a pipeline of small and large molecule particle-based ocular therapeutics
Healthios Role
If you would like to learn more information about this transaction contact us below.
